Gender-affirming hormone therapy and cardiovascular health in transgender adults

Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the effect of GAHT on cardiovascular outcomes are confounded by differences in GAHT regimens and methodological challenges in a diverse and historically hard-to-reach population. Current cardiovascular guidelines do not incorporate gender identity and hormone status into risk stratification and clinical decision-making. In this review, we provide an overview on the cardiometabolic impact and clinical considerations of GAHT for cardiovascular risk in transgender patients.PMID:38597210 | DOI:10.1080/13697137.2024.2310518
Source: Climacteric - Category: Geriatrics Authors: Source Type: research